"Corruption in any one of the critical decision points in the pharmaceutical system can be detrimental to a country’s ability to improve the health of its population." [World Banki]
"Are we becoming patients for profit? That is the question knowledgeable observers are asking.
Below a press release from the lawfirm, Baum Hedlund, announces it has filed a class action lawsuit against GlaxoSmithKline charging the company with fraud, negligence, strict liability, and breach of warranty in its marketing of Paxil (Seroxat) by concealing the risk of suicide.
"Biological psychiatrists have looked very closely for a serotonin imbalance or dysfunction in patients with depression or obsessive compulsive disorder and, to date, it has been elusive," says Dr. Wayne Goodman, Chair of the US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee.
Dr. Peter Breggin’s sealed expert medical report in a Paxil liability case is now in the public domain.
"During a hastily called press conference yesterday,” the FDA announced that it is considering ADDITIONAL warnings on the labels of SSRI drugs—Prozac, Paxil, Zoloft, et al.
It is astonishing how untrustworthy loosely given advice about the safety of SSRI antidepressants by medical professionals and academic institutions.
Big Pharma by Jacky Law reveals that in essence, most of the pharmaceutical industry’s claims are false; it is not the drug, but the placebo effect whose potency deserves almost all of the credit for any health improvement:
Authors of the American College of Neuropsychopharmacology Task Force on SSRIs and Suicidal Behavior in Youth: their known ties to the pharmaceutical industry
Even Dr. Robet Temple, FDA Medical Policy Director of the Center for Drug Evaluation & Research dismisses the claimed finidings of a flawed, but highly trumpeted recent SSRI study published in the American Journal of Psychiatry. The study was sponsored by the National Institute of Mental Health.
Two studies purporting to report “new encouraging” findings about the efficacy and safety of antidepressants—as tested in the “real world”—were published on Sunday by The American Journal of Psychiatry with an accompanying editorial by Dr. Thomas Insel, director of these studies’ funding agency, the National Institute of Mental Health.
